Acadia Pharmaceuticals | ACAD - Eps Gewinn Pro Aktie

Aktienkurs
21.97
Täglich Wechseln
-0.14 -0.63%
Monatlich
-0.18%
Jährlich
49.15%
Q2 Prognose
21.68

Fiscal Kalender Aktuell Konsens Zuletzt Datum
FY2026Q1 Mar/2026 0.07 0.11 May/06
FY2025Q4 Dec/2025 1.60 0.14 0.86 Feb/25
FY2025Q3 Sep/2025 0.42 0.14 0.20 Nov/05
FY2025Q2 Jun/2025 0.16 0.15 0.20 Aug/06
FY2025Q1 Mar/2025 0.11 0.01 0.10 May/07




Eps Veränderung Datum
Acadia Pharmaceuticals USD 1.6 1.18 2025-12
ALKERMES USD 0.29 0.2 2025-12
Alnylam Pharmaceuticals USD 1.25 1.65 2025-12
Biogen USD 1.99 2.82 2025-12
BioMarin Pharmaceutical USD 0.46 0.34 2025-12
Bristol-Myers Squibb USD 1.26 0.37 2025-12
Cara Therapeutics USD -0.59 4.45 2025-09
Corcept Therapeutics USD 0.2 0.04 2025-12
Cytokinetics USD -1.5 1.05 2025-12
Eisai JPY 60.94 24.92 2025-12
Eli Lilly USD 7.54 0.52 2025-12
Incyte USD 1.8 0.46 2025-12
J&J USD 2.7 0.24 2026-03
Moderna USD -2.11 1.6 2025-12
Neurocrine Biosciences USD 1.88 0.29 2025-12
Pfizer USD 0.66 0.21 2025-12
Prothena USD -0.46 0.22 2025-12
PTC Therapeutics USD -1.67 1.87 2025-12
Sarepta Therapeutics USD -3.58 3.45 2025-12
Ultragenyx Pharmaceutical USD -1.29 0.52 2025-12
Vanda Pharmaceuticals USD -0.09 0 2024-12
Vertex Pharmaceuticals USD 5.03 0.23 2025-12